Increasing costs of ADHD medications are putting pressure on patients as a shortage of Adderall forces them to carefully manage their budgets to afford necessary.
In the midst of a nationwide scarcity of ADHD medications, individuals are facing heightened financial burdens as they grapple with soaring prices for drugs essential in aiding concentration at school, work, and home.
Families are feeling the strain, compelled to explore
alternatives due to the scarcity, often limited to costly brand-name
medications. A USA TODAY analysis reveals an upward trajectory in the prices
paid by retail community pharmacies for various popular ADHD drugs. Since the
onset of the Adderall shortage in October 2022, these prices have not only
surpassed inflation but, in some instances, have doubled or even tripled.
A mother from Delaware, diagnosed with ADHD, shared with USA
TODAY that when the shortage of Adderall was announced, their doctor
transitioned her 17-year-old daughter to Vyvanse—the only alternative they
could find. This anecdote underscores the challenges faced by families
navigating the repercussions of the ongoing ADHD drug shortage.
he DEA has indicated that it is adapting its quota
regulations and collaborating with manufacturers to enhance the production of
ADHD stimulants. According to the agency's statement in early November, it has
been in contact with relevant manufacturers, and 17 out of 18 have affirmed
their intention to utilize their allocated quota amounts and boost the
production of stimulant medications.
Sandoz, in a written statement, acknowledged that the DEA
has been responsive to the company's requests for an increased quota, enabling
them to meet customer orders. While the resolution timeline for the shortage
remains uncertain, Ganio remarked that it is encouraging to witness the DEA's
proactive engagement with manufacturers and adjustments to its quota allocation
process.
Comments